Pilar Cazorla

619 total citations
29 papers, 494 citations indexed

About

Pilar Cazorla is a scholar working on Psychiatry and Mental health, Pharmacology and Physiology. According to data from OpenAlex, Pilar Cazorla has authored 29 papers receiving a total of 494 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Psychiatry and Mental health, 12 papers in Pharmacology and 12 papers in Physiology. Recurrent topics in Pilar Cazorla's work include Schizophrenia research and treatment (15 papers), Alzheimer's disease research and treatments (10 papers) and Treatment of Major Depression (8 papers). Pilar Cazorla is often cited by papers focused on Schizophrenia research and treatment (15 papers), Alzheimer's disease research and treatments (10 papers) and Treatment of Major Depression (8 papers). Pilar Cazorla collaborates with scholars based in United States, Spain and Switzerland. Pilar Cazorla's co-authors include Armin Szegedi, Karen L. O’Malley, J. Peter H. Burbach, Marten P. Smidt, Mary Mackle, Larry Alphs, John Panagides, Jun Zhao, Fernando Valdivieso and Jesús Vázquez and has published in prestigious journals such as Biochemical Journal, Biological Psychiatry and Journal of Neurochemistry.

In The Last Decade

Pilar Cazorla

27 papers receiving 482 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pilar Cazorla United States 14 239 131 127 77 63 29 494
A. Claus Germany 8 262 1.1× 81 0.6× 80 0.6× 60 0.8× 61 1.0× 10 531
L. Lannfelt Sweden 10 226 0.9× 210 1.6× 185 1.5× 95 1.2× 26 0.4× 12 597
Andrew Miller United States 12 393 1.6× 296 2.3× 221 1.7× 24 0.3× 121 1.9× 19 747
Paul Hollingworth United Kingdom 18 191 0.8× 316 2.4× 86 0.7× 371 4.8× 76 1.2× 24 802
Yoshimi Iijima Japan 17 164 0.7× 242 1.8× 187 1.5× 51 0.7× 23 0.4× 21 671
Károly Fazekas Hungary 8 225 0.9× 210 1.6× 196 1.5× 9 0.1× 83 1.3× 9 540
Shivakumar Kolachalam Italy 9 163 0.7× 200 1.5× 134 1.1× 59 0.8× 42 0.7× 13 500
Chiung-Hsien Huang Taiwan 8 154 0.6× 106 0.8× 89 0.7× 19 0.2× 21 0.3× 8 322
Nitin Rustogi United Kingdom 15 84 0.4× 229 1.7× 64 0.5× 150 1.9× 26 0.4× 23 567
Liina Haring Estonia 11 168 0.7× 140 1.1× 42 0.3× 112 1.5× 37 0.6× 25 469

Countries citing papers authored by Pilar Cazorla

Since Specialization
Citations

This map shows the geographic impact of Pilar Cazorla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pilar Cazorla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pilar Cazorla more than expected).

Fields of papers citing papers by Pilar Cazorla

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pilar Cazorla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pilar Cazorla. The network helps show where Pilar Cazorla may publish in the future.

Co-authorship network of co-authors of Pilar Cazorla

This figure shows the co-authorship network connecting the top 25 collaborators of Pilar Cazorla. A scholar is included among the top collaborators of Pilar Cazorla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pilar Cazorla. Pilar Cazorla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tariot, Pierre N., Marie‐Emmanuelle Riviere, Stephen Salloway, et al.. (2024). Reversibility of cognitive worsening observed with BACE inhibitor umibecestat in the Alzheimer's Prevention Initiative (API) Generation Studies. Alzheimer s & Dementia. 20(11). 7745–7761. 6 indexed citations
2.
Riviere, Marie‐Emmanuelle, Jessica B. Langbaum, Raymond Scott Turner, et al.. (2023). Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes. Alzheimer s & Dementia. 20(3). 1839–1850. 18 indexed citations
3.
Riviere, Marie‐Emmanuelle, Raymond Scott Turner, Jessica B. Langbaum, et al.. (2021). API generation program: Active immunotherapy CAD106 slows amyloid deposition in cognitively unimpaired APOE4 homozygotes. Alzheimer s & Dementia. 17(S9). 1 indexed citations
4.
Tariot, Pierre N., Beth Borowsky, Fonda Liu, et al.. (2020). The Generation program: Baseline characteristics of cognitively unimpaired APOE4 carriers recruited for Generation study 1 and Generation study 2. Alzheimer s & Dementia. 16(S9). 2 indexed citations
5.
Felip, Enriqueta, Filippo de Braud, Michela Maur, et al.. (2019). Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study. Journal of Thoracic Oncology. 15(3). 392–403. 60 indexed citations
6.
Kemp, David E., Jun Zhao, Pilar Cazorla, et al.. (2013). Weight Change and Metabolic Effects of Asenapine in Patients With Schizophrenia and Bipolar Disorder. The Journal of Clinical Psychiatry. 75(3). 238–245. 23 indexed citations
7.
Potkin, Steven G., et al.. (2013). Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: A pooled analysis. Schizophrenia Research. 150(2-3). 442–449. 21 indexed citations
8.
Cazorla, Pilar, et al.. (2013). Asenapine effects on individual Young Mania Rating Scale items in bipolar disorder patients with acute manic or mixed episodes: a pooled analysis. Neuropsychiatric Disease and Treatment. 9. 409–409. 13 indexed citations
9.
Szegedi, Armin, Paul E. Verweij, Wilbert van Duijnhoven, et al.. (2012). Meta-Analyses of the Efficacy of Asenapine for Acute Schizophrenia. The Journal of Clinical Psychiatry. 73(12). 1533–1540. 26 indexed citations
10.
Adler, Lenard A., Mark A. Stein, Mohammed Shahid, et al.. (2012). A Translational Approach to Evaluate the Efficacy and Safety of the Novel AMPA Receptor Positive Allosteric Modulator Org 26576 in Adult Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry. 72(11). 971–977. 47 indexed citations
11.
12.
Cazorla, Pilar, Jun Zhao, & Armin Szegedi. (2012). P-214 - Incidence, onset and duration of treatment-emergent somnolence with asenapine in patients with schizophrenia or bipolar disorder. European Psychiatry. 27. 1–1. 2 indexed citations
13.
Daniel, David G., Larry Alphs, Pilar Cazorla, John J. Bartko, & John Panagides. (2011). Training for Assessment of Negative Symptoms of Schizophrenia across Languages and Cultures: Comparison of the NSA-16 with the PANSS Negative Subscale and Negative Symptom Factor. Clinical Schizophrenia & Related Psychoses. 5(2). 87–94. 19 indexed citations
14.
Szegedi, Armin, Pilar Cazorla, & Jijun Zhao. (2011). P.3.c.059 Incidence, onset, and duration of treatment-emergent somnolence with asenapine in adult patients with schizophrenia or bipolar disorder. European Neuropsychopharmacology. 21. S502–S503.
15.
Potkin, Steven G., Jun Zhao, Larry Alphs, et al.. (2011). A pooled analysis of the effects of asenapine on the persistent negative symptoms of schizophrenia. European Psychiatry. 26(S2). 1510–1510. 3 indexed citations
16.
Cazorla, Pilar, et al.. (2008). ASENAPINE VERSUS OLANZAPINE IN PATIENTS WITH PREDOMINANT PERSISTENT NEGATIVE SYMPTOMS OF SCHIZOPHRENIA. Schizophrenia Research. 102(1-3). 252–252. 4 indexed citations
17.
Cazorla, Pilar, Marten P. Smidt, Karen L. O’Malley, & J. Peter H. Burbach. (2000). A Response Element for the Homeodomain Transcription Factor Ptx3 in the Tyrosine Hydroxylase Gene Promoter. Journal of Neurochemistry. 74(5). 1829–1837. 80 indexed citations
18.
Marina, Anabel, et al.. (1997). Anti-brain spectrin immunoreactivity in Alzheimer's disease: degradation of spectrin in an animal model of cholinergic degeneration. Journal of Neuroimmunology. 77(1). 91–98. 16 indexed citations
19.
Aldudo, Jesús, Pilar Cazorla, María J. Bullido, et al.. (1997). Proteolysis of Alzheimer's disease β-amyloid precursor protein by factor Xa. Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology. 1343(1). 85–94. 8 indexed citations
20.
Cazorla, Pilar, et al.. (1995). Location of an epitope shared by Alzheimer's amyloid peptide and brain creatine kinase using a newly developed monoclonal antibody. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1270(2-3). 149–156. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. Claus Breakdown of academic impact, for papers by L. Lannfelt Breakdown of academic impact, for papers by Andrew Miller Breakdown of academic impact, for papers by Paul Hollingworth Breakdown of academic impact, for papers by Yoshimi Iijima Breakdown of academic impact, for papers by Károly Fazekas Breakdown of academic impact, for papers by Shivakumar Kolachalam Breakdown of academic impact, for papers by Chiung-Hsien Huang Breakdown of academic impact, for papers by Nitin Rustogi Breakdown of academic impact, for papers by Liina Haring
Rankless by CCL
2026